Drug Approval | June 10, 2022
Sanofi Dupixent gets USFDA nod for atopic dermatitis
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Includes thermostabilized Ebola vaccines
‘Infinite Care’ comprises two key pillars - Sparsh Sankalpa and Sparsh Sukshema
The partnership will further strengthen Olympus leadership in the diagnosis and staging of liver disease
Pharmapack Europe recognizes excellence and innovation from exhibitors across connected devices, sustainability, supply chain logistics, route of administration, and packaging innovation, as well from the wider industry for patient-centric design and eco-design
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
Subscribe To Our Newsletter & Stay Updated
